Alan Wells, MD DMSc
Dr. Alan Wells is the Thomas J. Gill III Professor of Pathology and the Executive Vice-Chairman of the Department of Pathology at the University of Pittsburgh. In addition, Wells is a Professor of Bioengineering and Computational Biology (secondary appointments) and a Staff Physician at the Veterans Administration Medical Center in Pittsburgh, Pennsylvania. He also serves as the Medical Director for the UPMC System Clinical Laboratories.
Wells holds an AB in Biochemistry from Brown University (1979) and received his doctorate (DMSc) in Tumor Biology from the Karolinska Institute in Stockholm, Sweden, in 1982. Returning to Providence, Rhode Island, he received his MD from Brown University in 1988. Following his studies, Wells completed a postdoctoral fellowship in Tumor Biology at the University of California in San Francisco, California, and a Residency in Laboratory Medicine at the University of California in San Diego, California. He has won numerous awards and has been recognized locally and nationally for his research, mentoring and clinical service, including being elected to the American Society for Clinical Investigation (ASCI) and American Association of University Pathologists (AAUP/Pluto Club).
Within his laboratory, Wells and his research team are aiming to gain a better understanding of how cells respond to their local environment. Ultimately, the importance of his research flows from the provision of reinforcing insights and novel avenues for exploration into the basic signaling pathways, as well as functioning of entire organisms. Currently, Wells is concentrating his research efforts towards gaining further knowledge of the conditions of dysregulated (tumor dissemination and chemoresistance of tumors) and orchestrated (wound healing and organogenesis) responses. These studies are performed in vitro, in animal models, validating in human specimens, and employing novel state-of-the-art all human microphysiological systems.
Kenneth Liechty, MD
Dr. Kenneth Liechty’s research has been focused primarily in the field of wound healing, the response to injury, and regenerative medicine, with an emphasis on elucidating the mechanisms involved in the regenerative response to injury in the fetus, the role of inflammation and oxidative stress in tissue repair, and the correction of abnormal healing in the adult. Dr. Liechty’s research team has pioneered the role of dysregulated microRNAs in the diabetic wound healing impairment, and the mechanisms of the correction of this wound healing impairment with stem cell and gene therapy. The Liechty research team is developing novel treatment paradigms using small molecule therapeutics including the microRNA conjugated nanoparticles, as well as stem cells and gene therapy strategies to promote healing and tissue regeneration in multiple tissues by modulating the inflammatory response, angiogenesis, the composition of the extracellular matrix, macrophage polarization, and progenitor cell content. Dr. Liechty’s research team has also developed and published the first report of mammalian cardiac regeneration in a large animal model following in utero myocardial infarction and has contributed significantly to the understanding of regenerative healing in the heart, skin and tendon, and the correction of impaired healing in diabetics. The goal of Dr Liechty’s research approach in regenerative medicine is to restore normal tissue architecture and function and to prevent the complications of impaired healing or scar formation after injury.
The Ohio State University
1645 Neil Avenue
129 Hamilton Hall
Columbus, OH 43210
|Traci Wilgus, PhD, Vice-President (2021-2022)
Dr. Wilgus is an Associate Professor in the Department of Pathology at The Ohio State University. She earned her Ph.D. from Ohio State and completed post-doctoral training at Loyola University Medical Center. She was a junior faculty member at University of Illinois-Chicago before accepting a tenure-track position at Ohio State in 2008. Her lab studies the role of inflammation and angiogenesis in wound healing and skin carcinogenesis, with a special interest in understanding mechanisms of scarless healing in fetal skin. Dr. Wilgus frequently serves as a reviewer for manuscripts and grants in the area of wound healing and is a member of the editorial boards for Wound Management and Prevention, Advances in Wound Care, and Journal of Investigative Dermatology.
Dr. Wilgus joined the Wound Healing Society as a graduate student in 2000 and has served the WHS in various capacities over the last decade. She has served on the Website Committee (2008-2011) and Awards Committee (2011-2014), and has been a member of the Program Committee since 2010. She was Co-Chair of the WHS annual scientific meeting in 2015, served on the Board of Directors from 2013-2016, and was Secretary from 2016-2019.
Geoffrey Gurtner, MD, FACS
Vice Chairman of Surgery for Research
Stanford University School of Medicine
257 Campus Drive West, GK-201
Stanford, CA 94305-5148
|Past President (2021-2022)
Dr. Geoffrey C. Gurtner is the Johnson and Johnson Professor of Surgery and Biomedical Engineering (by courtesy) and Materials Science (by courtesy) at Stanford University. Clinically, Dr. Gurtner is the Director of the Stanford Wound Center and the Stanford Program in Applied Regenerative Medicine (SARM). He is the author of over 280 peer-reviewed publications and is an Editor for two major textbooks in the field: Grabb & Smith's Plastic Surgery and Plastic Surgery. Dr. Gurtner was awarded the James Barrett Brown Award in both 2009 and 2010 and has been named "researcher of the year" by the ASPS, AAPS and numerous other professional organizations. Dr. Gurtner runs an NIH and DoD funded laboratory examining how physical stimuli (mechanical and chemical) alter the human response to injury. This has led to the development of new technologies for which Dr. Gurtner has received 20 issued patents and over 100 patent applications. Dr. Gurtner has founded several venture backed start-up companies, including Neodyne Biosciences (www.neodynebio.com) and Arresto Biosciences, acquired by Gilead (NASDAQ:GILD) in 2011. Dr. Gurtner was also a founding partner at Tautona Group (www.tautonagroup.com), an early stage life science fund that has created novel biomedical technologies that have been sold to industry leading companies, such as Allergan (NYSE:AGN), Novadaq (NASDAQ:NVDQ), and Acelity/KCI (San Antonio, TX).
|Praveen Arany||Secretary (2019-2023)
Bio coming soon...
Herbert B. Slade, MD
Chisholm Clinical Research Services
2436 Medford Court West
Fort Worth, TX 76109
Dr. Slade is a dual board-certified subspecialist in pediatrics and clinical immunology with more than 25 years of industry-based experience in clinical research. After holding academic appointments at the University of Michigan and Cornell University Medical Center, he was recruited from academia to work with Dr. Jonas Salk on an HIV therapeutic vaccine joint venture, taking the position of Director of AIDS and Immunology at RhÃ´ne-Poulenc Rorer.
From there Dr. Slade went on to join 3M Pharmaceuticals as Chief Medical Officer. During his twelve years at 3M, Dr. Slade oversaw the development and licensure of multiple products, including a groundbreaking new class of immune response modifiers for viral infections and cancer. When 3M sold its pharma business, Dr. Slade joined DFB Pharmaceuticals in Fort Worth, TX, where he served as Chief Medical Officer for Healthpoint Biotherapeutics. Smith & Nephew plc acquired Healthpoint in 2012, bringing Dr. Slade into the realm of medical devices in the role of CMO and Sr.VP of Research & Development for the wound care division through the end of 2016.
Dr. Slade earned his undergraduate degree in biology from Hamilton College in Clinton, N.Y., followed by his medical degree from State University of New York (SUNY) Upstate Medical University in Syracuse, N.Y.
|Chandan Sen (2021-2024)
Dr. Chandan K. Sen is a Distinguished University Professor at Indiana University. He holds the J. Stanley Battersby Chair and serves as Professor of Surgery. He is an Associate Vice President of Research For IU. At Indiana University Health, Dr. Sen is the Founding Executive Director of the Comprehensive Wound Center. He is the Indiana PI for the NIH diabetic foot consortium. Dr. Sen directs the Indiana Center for Regenerative Medicine and Engineering (ICRME). At the IU School of Medicine, he serves as Associate Dean of Research. Dr. Sen is the Founding Editor-in-Chief of the WHS Journal Advances in Wound Care. After completing his Masters of Science in Human Physiology from the University of Calcutta, Dr. Sen received his PhD in Physiology from the University of Eastern Finland. Dr. Sen trained as a postdoctoral fellow at the University of California at Berkeley's Molecular and Cell Biology department. His first faculty appointment was in the Lawrence Berkeley National Laboratory. In 2000, Dr. Sen moved to The Ohio State University where he was tenured John H & Mildred C Lumley Professor of Surgery, Founding Executive Director of The Ohio State University Comprehensive Wound Center and Director of the Ohio State University's Center for Regenerative Medicine & Cell Based Therapies. Dr. Sen has published over 350 peer reviewed publications and a dozen books which are currently cited over 38000 times in the literature. He has a current H-index of 100.
|Susan Volk (2021-2024)
Susan Volk VMD, PhD, DACVS is a tenured Associate Professor of Small Animal Surgery at the University of Pennsylvania School of Veterinary Medicine. Dr. Volk earned both degrees in the Veterinary Medical Scientist Training Program and did her surgical residency at UPenn before assuming a faculty position in 2007. She has developed a research program focused on understanding dynamic reciprocity between cells and their surrounding extracellular matrix in both regenerative and tumor microenvironments. This NIH, private foundation, and industry sponsored research has basic and translational components, including clinical trials in veterinary patients. Dr. Volk also maintains an active clinical practice and teaches veterinary students, residents and graduate students.
New Indications Discovery Unit
Novartis Biomedical Research Institute
PO Box 290790
Charlestown, MA 02129
Work Phone: (253) 691-9197
|Vickie Rae Driver, DPM, MS (2018-2022)
Dr Vickie R. Driver is a Fellow at the American College of Foot and Ankle Surgeons, licensed in Ma and RI and is board certified in foot surgery by the American Board of Podiatric Surgery. She has recently been nominated as Fellow, Royal College of Physicians and Surgeons-Glasgow, PM. Her career has a special emphasis on wound healing and limb preservation and she is an outspoken ambassador for progressive change in this field.
Dr. Driver is a Professor of Surgery in the Department of Orthopedics at Brown University (Clinical). She has recently completed her tenure as president for the Advancement of Wound Care Association (AAWC), and has served for 9 years on the Board of Directors. She also proudly serves as a member of the Wound Healing Society (WHS) Board of Directors- member at large and chair-Industry relations and as member Board of Directors for the Critical Limb Ischemia (CLI) Global Society and chair wound healing committee.
She has successfully chaired an initiative to expand the wound healing clinical endpoints considered by FDA. She proposed a combined effort between the WHS and AAWC to develop the Wound-care Experts/FDA-Clinical Endpoints Project [WEF-CEP] to strategically identify clinically meaningful, evidence-based and patient-centered wound care endpoints that are relevant for clinical research and trials. The goal is to collaboratively work with the FDA to expand the list of acceptable primary endpoints, recognizing that new and innovative treatments, devices and drugs may not have complete healing as the focus. Furthermore, validated endpoints other than complete healing will promote improved clinical trial design and will reduce the time for discoveries to reach our patients. Over the past three years, through ongoing interaction with the FDA InterCenter Wound Healing Work Group [ICWHWG], the WEF-CEP team has conducted a wide reaching Clinician Survey with 628 participating wound care experts, completed an extensive literature review for 28 wound care endpoints using the FDA criteria for a validated endpoint, published the clinical survey results in WRR, is in process to publish the research phase results and is currently conducting a Patient Survey to augment the findings of the Clinician Survey. Formal collaboration with the FDA established to execute on the WEF CEP work is on-going.
As principle investigator, she has served on and initiated more than 70 important multi-center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs. She has co-authored over 100 publications and abstracts.
Dr. Driver is Director, Translational Medicine Wound Healing at Novartis Institute for BioMedical Research. She is dedicated to making a scientific contribution to both the understanding of the natural history of disease and the discovery of new therapies and diagnostics to advance the treatment of patients who suffer with wounds and are at risk of limb loss.
|Kath Bogie (2018-2022)
Dr. Bogie is a biomedical engineer committed to pursuing patient-centered translational research. Dr. Bogie currently holds appointments as Associate Professor in the Dept of Orthopaedics at Case Western Reserve University (CWRU) and as Senior Research Scientist at the Louis Stokes Cleveland Dept of Veterans Affairs Medical Center, where she is also Director of Health Maintenance and Monitoring within the Advanced Platform Technology Center. At CWRU, she directs the Additive Manufacturing for Biotechnology Core, supporting biomedical additive manufacturing. Dr. Bogie received her D.Phil in Biomedical Engineering from the University of Oxford, England. Her initial post-doctoral appointment was at the National Spinal Cord Injuries Centre (NSIC), Aylesbury, England, with a concurrent appointment as Associate Clinical Scientist at Queen Mary and Westfield College, University of London. At NSIC, she established a Wheelchair Seating Clinic for individuals with spinal cord injury. The multivariate quantitative non-invasive tissue health evaluation tool she developed there has since been applied in multiple clinical studies. At NSIC, she noticed that many wheelchair users were prevented from achieving their full functional potential due to tissue health problems. The huge detriment on all aspects of the affected individual's life motivated her to dedicate her career to the multiple challenges of wound management. Dr. Bogie's lab works on primary and secondary prevention of chronic wounds through novel clinically –focused approaches. The overarching goal is to reduce the fear of developing a chronic non-healing wound. Dr. Bogie has received continuous support for her research program for over 17 years, including funding from the DoD Spinal Cord Injury Research Program, the Dept. of Veterans Affairs Rehabilitation Service and the Craig H Neilsen Foundation. Current translational research includes studies to determine why some people experience a continuous cycle of pressure injuries while others remain pressure injury free, complemented with smart technology development to address these issues. Dr. Bogie has been recognized internationally as an expert in research areas related to wound care, has published over 50 papers and book chapters and given multiple national and international presentations. Dr Bogie is on the Editorial Boards of Journal of Tissue Viability and the Journal of Rehabilitation and Assistive Technologies Engineering and is an active referee for multiple scientific journals and numerous other national and international grant review panels.
Dr. Bogie joined the Wound Healing Society in 2011, and has served as an active member of the Education Committee since joining WHS. As a biomedical engineer working on translational studies in wound care, Dr. Bogie is committed to building effective interdisciplinary teamwork. There are a wealth of basic science and early clinical trials being carried out in wound care research, but all too often these fail to translate, in part due to lack of communication between different specialties. The Wound Healing Society is the home that fosters interactions. Moving outside our silos of expertise and working with others allows the field to gain from diversity of experience. As a member of the WHS Board of Directors, Dr. Bogie looks forward to working to enhance interdisciplinary interactions in wound care research.
|Rivkah Isseroff (2018-2022)
Bio coming soon...
|Brian Eliceiri (2019-2023)
Brian Eliceiri, PhD was the co-chair for the Annual WHS meeting held in San Diego 2017, and is currently a Board member for the WHS. He received his B.A. from Washington University in St. Louis, a PhD from Johns Hopkins University in Baltimore, post-doctoral training at the Scripps Research Institute in San Diego, and is a Professor in the Department of Surgery at the University of California San Diego. His research is focused on mechanisms regulating immune homeostasis, with specific interests in the biogenesis of exosomes mediating immune cell crosstalk and trafficking of immune cells from the blood. Using physiological models of inflammation and cancer, he has developed genetic and pharmacological approaches to define specific mechanisms regulating the recruitment activation of immune cells in response to acute and chronic injury. Through inter-disciplinary collaborations, his lab has developed tools for the study of unique human genes and engineered animal models for the study of inflammation with a focus on exosomes and their regulation of innate-adaptive immune cell crosstalk that can translate from experimental models into the clinic.
|Timothy King (2019-2023)
Bio coming soon...
|Lisa Gould (2019-2023)
Bio coming soon...
Members at Large
Representing Wound Healing Society Foundation on the Board of Directors
Laura K.S. Parnell Ex-Officio
Founder & President
6522 Harbor Mist
Missouri City, TX 77459
Representing Wound Repair and Regeneration on the Board of Directors
To contact a Board member, please email WHS or call 978-927-8330.